58 related articles for article (PubMed ID: 24615021)
1. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
2. The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors.
Galvano A; Gristina V; Scaturro D; Bazan Russo TD; Tomasello S; Vitagliani F; Carità F; La Mantia M; Fulfaro F; Bazan V; Mauro GL; Russo A
Front Endocrinol (Lausanne); 2023; 14():1297950. PubMed ID: 38075057
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density.
Sayed SA; El Wakeel LM; Elseasi AM; Shawki MA
Pharmacotherapy; 2023 Sep; 43(9):904-912. PubMed ID: 37323099
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density response to antiosteoporotic drugs in older depressed adults.
Efendioglu EM; Cigiloglu A; Ozturk E; Ozturk ZA
Arch Osteoporos; 2023 Feb; 18(1):31. PubMed ID: 36781548
[TBL] [Abstract][Full Text] [Related]
5. Transient osteoporosis of the hip following discontinuation of denosumab and switch to alendronate treatment.
Makras P; Yavropoulou MP; Anastasilakis AD; Papatheodorou A; Tekedis C; Papapoulos SE
Osteoporos Int; 2024 Apr; 35(4):741-743. PubMed ID: 38147135
[No Abstract] [Full Text] [Related]
6. Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study.
Yahyavi SK; Holt R; Knudsen NK; Andreassen CH; Sejling C; Meddis A; Kjaer SK; Schwarz P; Jensen JB; Torp-Pedersen C; Juul A; Selmer C; Blomberg Jensen M
Bone; 2024 May; 182():117053. PubMed ID: 38395247
[TBL] [Abstract][Full Text] [Related]
7. An Uncommon Cause of Debilitating Hip Pain in Pregnancy.
Sifrig B; Grozenski A; Brown L; Coleman J
Curr Sports Med Rep; 2021 Feb; 20(2):80-83. PubMed ID: 33560030
[No Abstract] [Full Text] [Related]
8. Correction to: The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
Ramchand SK; Tsai JN; Lee H; Sassana-Khadka G; Jordan M; Ryan S; Leder BZ
Osteoporos Int; 2024 Feb; 35(2):371. PubMed ID: 37940698
[No Abstract] [Full Text] [Related]
9. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
10. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.
Choi E; Buie J; Camacho J; Sharma P; de Riese WTW
Res Rep Urol; 2022; 14():87-108. PubMed ID: 35386270
[TBL] [Abstract][Full Text] [Related]
12. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
13. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
14. Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Wu C; Chen W; Huang X; Lin R; Wu J; Zhang X
Clin Genitourin Cancer; 2018 Dec; 16(6):e1243-e1250. PubMed ID: 30146230
[TBL] [Abstract][Full Text] [Related]
15. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
16. Bone mass behavior after 1 year of different treatment strategies in prostate cancer patients subjected to androgen deprivation therapy.
Planas Morin J; Celma Domenech A; Placer Santos J; Trilla Herrera E; Salvador Lacambra C; Lorente Garcia D; Regis L; Carles Galceran J; Morote Robles J
Rheumatol Int; 2014 Oct; 34(10):1419-25. PubMed ID: 24615021
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation in prostate cancer and the long-term risk of fracture.
Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
